MMMariana Letícia de Bastos Maximiano

Mariana Letícia de Bastos Maximiano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mariana Letícia de Bastos Maximiano has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Reply to “Caution Needed Regarding Conclusions of Meta-Analysis of Coenzyme Q10 as Treatment for Depressive Symptoms”

    by Pedro Lucas Machado Magalhães, Anderson Matheus Pereira da Silva, Mariana Letícia de Bastos Maximiano, Alice de Aquino Tavares Fortes, Dillan Cunha Amaral, Luiza de Oliveira Silva, Beatriz Dias da Silva Teixeira

    Was not provided for this article.

  • Glucagon‐like peptide‐1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta‐analysis

    by Luciano Falcão, Leonardo B. O. Brenner, Pedro Lucas Machado Magalhães, Abhishek Goyal, Mariana Leticia de Bastos Maximiano, Kenzo Ogasawara Donato, Rafael Andrade Sampaio Silva, Joao Victor Pereira Gonzalez, Anderson Matheus Pereira da Silva, Anderson Silva Corin, et al.

    Objectives/Background: Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), initially developed for type 2 diabetes and obesity, have emerged as promising candidates for idiopathic intracranial hypertension (IIH) due to their metabolic and neurophysiological effects. This systematic review and meta‐analysis aims to summarize, synthesize, and quantitatively pool the available evidence on the use of GLP‐1 RAs in patients with IIH, focusing on clinical outcomes. Methods: PubMed, Embase, Web of Science, and the Cochrane Library were searched through December 2025 for randomized trials and cohort studies assessing GLP‐1 RAs in patients with IIH. Risk of bias was assessed by Risk of Bias in Nonrandomized Studies of Interventions and Cochrane Risk of Bias 2.0. Primary outcomes included papilledema, headache burden, refractory IIH, and visual disturbances. Results: Eight studies comprising 13,243 patients met inclusion criteria. GLP‐1 RAs significantly reduced papilledema risk at 3 months (risk ratio [RR], 0.430; 95% confidence interval [CI], 0.281–0.659; I ‐squared statistic [ I 2 ] = 62.5%) and maintained the benefit through 24 months (RR, 0.469; 95% CI, 0.382–0.576; I 2 = 18.0%). Headache frequency was also consistently lower at 3 months (RR, 0.690; 95% CI, 0.557–0.853; I 2 = 71.0%) and at 24 months (RR, 0.796; 95% CI, 0.691–0.916; I 2 = 68.9%), with similar improvements in visual disturbances at 3 months (RR, 0.408; 95% CI, 0.304–0.547; I 2 = 36.0%) and 24 months (RR, 0.433; 95% CI, 0.236–0.796; I 2 = 79.0%), and refractory IIH at 3 months (RR, 0.696; 95% CI, 0.574–0.843; I 2 = 60.0%) and 24 months (RR, 0.808; 95% CI, 0.715–0.908; I 2 = 52.0%) compared to control group. Conclusion: GLP‐1 RAs appear associated with improvements in clinical outcomes in IIH, including reductions in papilledema, headache, and visual symptoms. The current evidence base is dominated by observational studies with moderate to serious risk of confounding, resulting in low‐certainty, hypothesis‐generating evidence. These findings should be interpreted cautiously and primarily serve to inform the design of future well powered randomized controlled trials.


  • Reperfusion therapy in pregnant and postpartum women after ischemic stroke: a systematic review and single-arm meta-analysis

    by Lucca Tamara Alves Carretta, Ocilio Ribeiro Gonçalves, Izabely dos Reis de Paula, Elizabeth Honorato de Farias, Sandy Souza, Mariana Letícia de Bastos Maximiano, Marianna Leite, Rafael Torres Fonseca dos Santos, Filipe Virgilio Ribeiro, André Nishizima, et al.

    Ischemic stroke during pregnancy and postpartum represents a rare but severe clinical event. Although reperfusion therapies like intravenous thrombolysis (IVT) and mechanical thrombectomy (MT) are standard in the general population, their use in pregnant and postpartum patients remains controversial due to limited data. Therefore, this study aims to evaluate the safety and efficacy of reperfusion therapy in pregnant and postpartum women with acute ischemic stroke. Systematic review and single-arm meta-analysis of studies reporting outcomes in pregnant or postpartum women undergoing IVT or MT. Outcomes included maternal and fetal events, intracerebral hemorrhage (ICH), symptomatic ICH (sICH), functional recovery (mRS 0-2), and mortality. Six studies comprising 275 patients were included. The pooled proportion of good maternal outcomes at discharge was 50% (95% CI: 44%-56%), and 85% (95% CI: 53%-100%) achieved functional recovery at 3 months. In-hospital mortality was 0% (95% CI: 0%-1%). Hemorrhagic complications included 10% ICH (95% CI: 1%-20%) and 3% sICH (95% CI: 0%-9%). Good fetal outcomes were observed in 78% (95% CI: 50%-100%) of cases. Although limited, the results suggest that reperfusion therapy in pregnancy-related ischemic stroke is safe and potentially effective, with favorable maternal and fetal outcomes and low mortality rates. These findings support the use of reperfusion therapies associated with individualized decision-making-in line with European Stroke Organisation guidelines -, emphasizing that pregnancy and post-partum period should not be a contraindication to IVT or MT.


  • Efficacy and safety of modafinil in post-stroke fatigue: a systematic review and meta-analysis

    by Iago Nathan Simon Petry, Gabriel Caruso Novaes Tudella, Mariana Letícia de Bastos Maximiano, Yasmin Picanco Silva, João Victor Pereira Gonzalez, Leonora Ramlow Leodoro da Silva, João Antônio Ramlow Leodoro da Silva, Giovanna Cristina Gonçalves Camacho, Marcos de Oliveira Machado, Luis Gustavo Biondi Soares, et al.

    Post-stroke fatigue (PSF) is a common and disabling condition that limits rehabilitation and quality of life, yet no pharmacological treatment is well established. Modafinil, a wakefulness-promoting agent, has been proposed as a potential therapy. This systematic review and meta-analysis evaluated its efficacy and safety in PSF. Four studies (two RCTs, two observational) comprising 1001 met inclusion criteria. Modafinil did not significantly improve overall fatigue severity on the MFI or FSS. A domain-specific benefit was observed for mental fatigue (MD -2.51; p = 0.0005), with no significant effects on physical, general, or activity-related fatigue. No improvements were found in quality of life (SSQoL) or cognition (MoCA). Modafinil was generally well tolerated with few mild adverse events. Current evidence does not support modafinil as a routine treatment for PSF. Its effect on mental fatigue is of very low certainty, limiting the strength of this finding. Clinicians should interpret these findings cautiously, and use modafinil only on a case-by-case basis. Larger, high-quality trials with standardized fatigue measures are needed to identify responders and clarify its clinical role.

  • Dual antiplatelet therapy pretreatment in patients undergoing intravenous thrombolysis for acute ischemic stroke: a systematic review and meta-analysis of 296,854 patients

    by Mariana Letícia de Bastos Maximiano, Ocílio Ribeiro Gonçalves, Luciano Falcão, Lucca Tamara Alves Carretta, Mariana Lee Han, João Vitor Andrade Fernandes, Lucas Pari Mitre, Filipe Virgilio Ribeiro, Paweł Łajczak, Fábio de Melo Franzoni, et al.

    Wea im to evaluate the impact of Dual Antiplatelet Therapy (DAPT) pretreatment on outcomes in patients with Acute Ischemic Stroke (AIS) undergoing intravenous thrombolysis (IVT). A systematic search was conducted from inception to January 2025. Eligible studies included randomized and observational cohorts comparing AIS patients with and without DAPT pretreatment who underwent IVT. Primary outcome was favorable functional outcome at 90 days (mRS 0-1). Secondary outcomes included mRS 0-2, mRS 3-6, in-hospital and 90-day mortality, and symptomatic intracranial hemorrhage (sICH) defined by SITS-MOST, ECASS II, and NINDS criteria. Risk of bias was assessed using the ROBINS-I tool, and meta-analyses were performed with random-effects models. Eight studies including 296,854 patients (61,925 with DAPT and 234,929 without DAPT) were analyzed. DAPT pretreatment was not associated with favorable functional outcome (mRS 0-1; OR: 1.03; 95% CI: 0.92-1.16; p = 0.57; I2 = 0%), in-hospital mortality (OR: 1.00; 95% CI: 1.00-1.00; I2 = 0%), or 90-day mortality (OR: 1.49; 95% CI: 0.99-2.25; p = 0.06; I2 = 52%). No significant increase in sICH was observed using SITS-MOST (I2 = 64%) or ECASS II (I2 = 63%), whereas sICH defined by NINDS was increased (OR: 1.31; 95% CI: 1.19-1.44; p < 0.01; I2 = 48%), corresponding to a 1% absolute risk increase (RD: 0.01; I2 = 0%). Prestroke DAPT was not associated with favorable functional outcome or reduced mortality after IVT and was associated with a higher risk of sICH when defined by NINDS criteria, with a 1% absolute risk increase.

  • Efficacy and safety of Pipeline Embolization Device versus Tubridge flow diverter for unruptured intracranial aneurysms: a systematic review and meta-analysis

    by Gabriel Arruda, Ocílio Ribeiro Gonçalves, Pedro Lucas Machado Magalhães, João Vitor Andrade Fernandes, Maria Tereza Camarotti, Filipe Virgilio Ribeiro, Mariana Letícia de Bastos Maximiano, Jhon E. Bocanegra-Becerra, Ahmet Günkan, Márcio Yuri Ferreira, et al.

    To compare the outcomes of flow diversion treatment with Pipeline Embolization Device (PED) and Tubridge Flow Diverter (TFD) in unruptured intracranial aneurysms. A systematic review and meta-analysis were conducted in accordance with PRISMA 2020 guidelines. The primary outcome was complete aneurysm occlusion. Secondary outcomes included favorable functional outcomes (modified Rankin Scale 0-2), perioperative ischemic and hemorrhagic complications, and in-stent stenosis. Risk ratios (RR) with 95% confidence intervals (CI) were pooled using the Mantel-Haenszel method under a random-effects model. Heterogeneity was assessed using the I2 statistic. Statistical analyses were performed using R software (version 4.4.0). Four studies including 913 patients were analyzed; 462 underwent treatment with TFD and 451 with PED. Complete aneurysm occlusion was achieved in 75.96% of TFD cases and 81.64% of PED cases (RR: 0.93; 95% CI: 0.87-1.00; I2 = 0%). Favorable functional outcomes occurred in 97.07% (TFD) and 96.84% (PED) (RR: 1.00; 95% CI: 0.98-1.02; I2 = 0%). Ischemic complications were slightly higher in TFD (4.11%) than in PED (2.44%) (RR: 1.67; 95% CI: 0.39-7.10; I2 = 53.7%). Hemorrhagic complications were low in both groups (0.26% vs. 0.54%; RR: 0.55; 95% CI: 0.07-4.39; I2 = 0%). In-stent stenosis occurred in 15.06% (TFD) and 16.08% (PED) (RR: 0.94; 95% CI: 0.66-1.33; I2 = 0%). PED and TFD demonstrate comparable efficacy and safety profiles for the treatment of unruptured intracranial aneurysms. Both devices are effective options for endovascular therapy.


  • Effects of Coenzyme Q10 Supplementation on Depressive Symptoms and Fatigue

    by Pedro Lucas Machado Magalhães, Anderson Matheus Pereira da Silva, Mariana Letícia de Bastos Maximiano, João Vitor Andrade Fernandes, Dillan Cunha Amaral, Alice de Aquino Tavares Fortes, Helvécio Neves Feitosa Filho, Luiza de Oliveira Silva, Beatriz Dias da Silva Teixeira, Eryvelton de Souza Franco, et al.

    Background: Coenzyme Q10 (CoQ10) is a mitochondrial cofactor with antioxidant and anti-inflammatory properties that may counteract mechanisms implicated in depression, such as oxidative stress and mitochondrial dysfunction. We evaluated the efficacy of CoQ10 supplementation on depressive symptoms and fatigue in patients with depression, whether as a primary disorder or in the context of underlying medical illness. Methods: A systematic review and meta-analysis was conducted according to PRISMA guidelines. Randomized controlled trials comparing CoQ10 with placebo or standard treatment in patients diagnosed with depression were eligible, independent of concomitant medical conditions. Outcomes included changes in depressive symptoms and fatigue. Data were pooled using random-effects models, with standardized mean differences (SMD) and 95% CIs. Heterogeneity was assessed with the I 2 statistic, and sensitivity analyses were performed using a leave-one-out approach. Results: Five RCTs with 474 participants were included. Three trials enrolled patients with depression associated with significant medical conditions—multiple sclerosis, breast cancer, and polycystic ovary syndrome—while 2 included patients with primary depressive disorders (major depression and bipolar disorder). CoQ10 supplementation significantly reduced depressive symptoms compared with control (SMD: −0.68; 95% CI: −1.02 to −0.33; P I 2 =58%), with consistent results across rating scales. Sensitivity analysis indicated that heterogeneity was largely driven by a single study. No significant benefit was observed for fatigue (SMD: −0.33; 95% CI: −1.38 to 0.72; P =0.54; I 2 =89%), based on only 2 trials. Conclusions: CoQ10 supplementation may confer moderate improvement in depressive symptoms across diverse populations. However, the evidence for fatigue remains inconclusive.


  • The diagnostic accuracy of artificial intelligence models in detecting lymph node metastases in lung cancer using endobronchial ultrasound (EBUS) images: A bivariate meta-analysis

    by Victor Arthur Ohannesian, Luciano Falcão, Bruno Marçola Ishizuka, Isabelle Rodrigues Menezes, Mariana Lee Han, Ricardo F.O. Suruagy-Motta, Mariana Letícia B. Maximiano, Davi M.H. Cordeiro, João Marcelo Baptista, Miriana Mariussi, et al.


  • Decompressive craniectomy versus best medical treatment alone for spontaneous intracerebral hemorrhage: A systematic review and meta-analysis

    by Rafael Reis de Oliveira, Yasmin Picanço Silva, Yusuf-Zain Ansari, Mariana Letícia de Bastos Maximiano, Leonardo B. O. Brenner, Iago Nathan Simon Petry, Mariana Lee Han, Júlia dos Santos Monteiro, Raphael Leal Dias da Silva, Laiana Neves Cordeiro Cavalcanti, et al.

    Background: While managing spontaneous intracerebral hemorrhage (sICH) has advanced, achieving favorable outcomes remains challenging. Recent studies suggest that decompressive craniectomy (DC) may offer benefits over conservative treatment, consisting of the best medical treatment (BMT) in certain sICH cases. Aim: This study aims to compare DC to BMT alone for sICH regarding functional neurological outcomes, mortality, and length of hospitalization. Methods: Randomized and observational studies were identified comparing surgery (DC) to conservative management alone for patients with sICH. The outcomes analyzed were modified Rankin Scale (mRS), mortality at 30 days, 90 days, and overall mortality, and length of hospital stay. The odds ratio (OR) and mean difference (MD) were calculated for binary and continuous outcomes. Results: Our analysis included eight studies (n = 743), with 345 patients undergoing surgery and 398 undergoing conservative management. BMT alone was associated with a poor neurological function (mRS of 5–6) (OR = 0.44; 95% CI = 0.24–0.78; p-value = 0.005; I 2 = 39.8%), while the rate of good neurological function (mRS = 0–4) was superior in the surgical cohort (OR = 2.29; 95% CI = 1.28–4.10; p = 0.005; I 2 = 39.8%), despite the lack of statistical significance for mRS 0–2 (OR = 1.25; 95% CI = 0.47–3.33; p = 0.66; I 2 = 0%) and mRS 0–3 (OR = 1.43; 95% CI = 0.82–2.51; p = 0.21; I 2 = 0%). Conservative management was associated with higher mortality at 30 days (OR = 0.36; 95% CI = 0.19–0.66; p-value = 0.001; I 2 = 0%), at 90 days (OR = 0.35; 95% CI = 0.14–0.86; p = 0.022; I 2 = 68.7%), and at last follow-up (OR = 0.33; 95% CI = 0.21–0.52; p-value < 0.001; I 2 = 34.8%). Length of hospital stay was superior in the DC cohort, but without statistical significance (MD = 16.05; 95% CI = −3.24 to 35.34; p-value = 0.1; I 2 = 92.9%). Conclusions: In patients with sICH, decompressive craniectomy shows potential for reducing mortality and improving neurological function compared to BMT alone. Further randomized studies, with improved methods, are needed to increase the quality of evidence.


  • Open Access

    Prognostic biomarkers in ischemic stroke treated with mechanical thrombectomy: a systematic review

    by Rodrigo Fellipe Rodrigues, Raquel Cristina Trovo Hidalgo, Savio Batista, Júlia Belone Lopes, Gabriel Paulo Mantovani, Pedro Henrique Matos Oliveira, André Nishizima, Anderson Silva Corin, Lucas Macedo, Mariana Letícia de Bastos Maximiano, et al.

    Mechanical thrombectomy (MT) is a key therapy for acute ischemic stroke (AIS), improving survival and functional outcomes. However, the variability in results highlights the need for predictive markers to refine patient selection. Biomarkers reflecting inflammation and metabolic stress are gaining recognition for their role in AIS and MT outcomes. To systematically review and synthesize the evidence on biomarkers associated with clinical outcomes in AIS patients undergoing MT. Specific aims include evaluating their relationship with functional recovery (mRS), mortality, infarct volume, hemorrhagic transformation, and complications such as malignant brain edema (MBE) and delayed cerebral ischemia (DCI). A systematic review of the literature was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement to identify studies evaluating biomarkers in MT. The PubMed and Embase databases were searched using the following terms: (Marker OR biomarker*) AND (Mechanical Thrombectomy OR endovascular) AND Stroke. Of 2,834 articles identified, 86 met inclusion criteria. Several biomarkers, such as C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), adenosine deaminase (ADA), neuron-specific enolase (NSE), and matrix metalloproteinase-9 (MMP-9), were consistently associated with worse functional outcomes, increased mortality, and higher risk of complications including hemorrhagic transformation and MBE. Multiple biomarkers demonstrate prognostic value in AIS patients undergoing MT. These findings may support risk stratification and individualized care, though further prospective studies are needed to integrate these biomarkers into the clinical practice.